Comparison of no adjuvant treatment and radiotherapy in early-stage cervical carcinoma with intermediate risk factors

被引:15
作者
Akilli, Huseyin [1 ]
Tohma, Yusuf A. [2 ]
Bulut, Ayca N. [3 ]
Karakas, Latife Atasoy [2 ]
Haberal, Asuman N. [4 ]
Kuscu, Ulku E. [1 ]
Ayhan, Ali [1 ]
机构
[1] Baskent Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Sch Med, Ankara, Turkey
[2] Baskent Univ, Dept Obstet & Gynecol, Sch Med, Ankara, Turkey
[3] City Hosp, Dept Obstet & Gynecol, Kayseri, Turkey
[4] Baskent Univ, Dept Pathol, Sch Med, Ankara, Turkey
关键词
Adjuvant treatment; Disease-free survival; Early-stage cervical cancer; Intermediate risk factors; Local recurrence; Radiotherapy; RADICAL HYSTERECTOMY; RADIATION-THERAPY; CANCER-PATIENTS; IB; CHEMOTHERAPY; SURGERY;
D O I
10.1002/ijgo.13147
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the results of receiving no adjuvant treatment (NAT) or radiotherapy after radical hysterectomy in patients with International Federation of Gynecology and Obstetrics 2018 Stage IB1-IB3 cervical cancer with intermediate risk factors. Methods A retrospective cohort study was conducted at Baskent University School of Medicine's Department of Gynecology and Obstetrics in Ankara, Turkey between January 1, 2008, and December 31, 2016. In total, 134 women with at least two intermediate risk factors (positive LVSI, deep stromal invasion, and tumor size >= 4 cm) were included in the study. Patients were divided into two groups: NAT and radiotherapy. Results There were 66 patients in the NAT group and 68 in the radiotherapy group. The median follow-up time was 61.05 months. The 5-year overall survival (OS) rates were similar in both groups (84.1% vs 82.9%, respectively; P=0.57), while the 5-year disease-free survival (DFS) rates were 80.2% and 78.2% in the NAT and radiotherapy groups, respectively (P=0.25). Most importantly, both groups had similar local recurrence rates: 8 (12.1%) in the NAT group and 9 (13.2%) in the radiotherapy group (P=0.82). Multivariant analyses showed that the only independent risk factor for recurrence was tumor size >= 4 cm with a hazard ratio of 2.4 (95% confidence interval 1.12-5.24; P=0.02). Conclusion Adjuvant treatment improved neither DFS nor local recurrence rates.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 19 条
  • [1] AYHAN A, 1991, EUR J SURG ONCOL, V17, P492
  • [2] BILEK K, 1982, ARCH GESCHWULSTFORSC, V52, P223
  • [3] Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature
    Cibula, David
    Abu-Rustum, Nadeem R.
    Fischerova, Daniela
    Pather, Selvan
    Lavigne, Katie
    Slama, Jiri
    Alektiar, Kaled
    Ming-Yin, Lin
    Kocian, Roman
    Germanova, Anna
    Fruhauf, Filip
    Dostalek, Lukas
    Dusek, Ladislav
    Narayan, Kailash
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 438 - 443
  • [4] The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer
    Cibula, David
    Poetter, Richard
    Planchamp, Francois
    Avall-Lundqvist, Elisabeth
    Fischerova, Daniela
    Haie-Meder, Christine
    Koehler, Christhardt
    Landoni, Fabio
    Lax, Sigurd
    Lindegaard, Jacob Christian
    Mahantshetty, Umesh
    Mathevet, Patrice
    McCluggage, W. Glenn
    McCormack, Mary
    Naik, Raj
    Nout, Remi
    Pignata, Sandro
    Ponce, Jordi
    Querleu, Denis
    Raspagliesi, Francesco
    Rodolakis, Alexandros
    Tamussino, Karl
    Wimberger, Pauline
    Raspollini, Maria Rosaria
    [J]. VIRCHOWS ARCHIV, 2018, 472 (06) : 919 - 936
  • [5] Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan
    Ikeda, Yuji
    Furusawa, Akiko
    Kitagawa, Ryo
    Tokinaga, Aya
    Ito, Fuminori
    Ukita, Masayo
    Nomura, Hidetaka
    Yamagami, Wataru
    Tanabe, Hiroshi
    Mikami, Mikio
    Takeshima, Nobuhiro
    Yaegashi, Nobuo
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (03)
  • [6] Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors
    Kim, K.
    Kang, S. B.
    Chung, H. H.
    Kim, J. W.
    Park, N. H.
    Song, Y. S.
    [J]. EJSO, 2009, 35 (02): : 192 - 196
  • [7] Cervical Cancer, Version 3.2019
    Koh, Wui-Jin
    Abu-Rustum, Nadeem R.
    Bean, Sarah
    Bradley, Kristin
    Campos, Susana M.
    Cho, Kathleen R.
    Chon, Hye Sook
    Chu, Christina
    Clark, Rachel
    Cohn, David
    Crispens, Marta Ann
    Damast, Shari
    Dorigo, Oliver
    Eifel, Patricia J.
    Fisher, Christine M.
    Frederick, Peter
    Gaffney, David K.
    Han, Ernest
    Huh, Warner K.
    Lurain, John R., III
    Mariani, Andrea
    Mutch, David
    Nagel, Christa
    Nekhlyudov, Larissa
    Fader, Amanda Nickles
    Remmenga, Steven W.
    Reynolds, R. Kevin
    Tillmanns, Todd
    Ueda, Stefanie
    Wyse, Emily
    Yashar, Catheryn M.
    McMillian, Nicole R.
    Scavone, Jillian L.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01): : 64 - 84
  • [8] Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Marth, C.
    Landoni, F.
    Mahner, S.
    McCormack, M.
    Gonzalez-Martin, A.
    Colombo, N.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 72 - 83
  • [9] Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer
    Matsuo, Koji
    Shimada, Muneaki
    Yokota, Harushige
    Satoh, Toyomi
    Katabuchi, Hidetaka
    Kodama, Shoji
    Sasaki, Hiroshi
    Matsumura, Noriomi
    Mikami, Mikio
    Sugiyama, Toru
    [J]. ONCOTARGET, 2017, 8 (63) : 106866 - 106875
  • [10] Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study)
    Nakamura, Kazuto
    Kitahara, Yoshikazu
    Satoh, Toyomi
    Takei, Yuji
    Takano, Masashi
    Nagao, Shoji
    Sekiguchi, Isao
    Suzuki, Mitsuaki
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14